



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Atacept

Cat. No.:	HY-P99446
CAS No.:	845264-92-8
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Atacept (TACI-Ig) is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacept can be used in research of B-cell autoimmune disease <sup>[1][2]</sup> .																
<b>In Vivo</b>	<p>Atacept (TACI-Ig; 100 µg; i.p.; three times of week for 14 days; BALB/c mice) reduces mature B-cell counts and serum antibody levels in normal mice<sup>[1]</sup>.</p> <p>Atacept (TACI-Ig) inhibits the progression of disease and autoantibody titers in a mouse model of collagen-induced arthritis (CIA)<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male DBA/1 mice with CIA models<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>100 µg</td> </tr> <tr> <td>Administration:</td> <td>intraperitoneal injection; three times of week for 21 days</td> </tr> <tr> <td>Result:</td> <td>Increased serum titers of anti-collagen Abs and few overt signs of disease.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>BALB/c mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>100 µg</td> </tr> <tr> <td>Administration:</td> <td>intraperitoneal injection; three times of week for 14 days</td> </tr> <tr> <td>Result:</td> <td>Reduced mature B cell populations but had little effect on other cell lineages. Blocked the development of B cells at the transition from T1 to T2 and the development of MZ B cells in the spleen. Decreased the serum levels of IgM about 2.3-fold.</td> </tr> </table>	Animal Model:	Male DBA/1 mice with CIA models <sup>[1]</sup>	Dosage:	100 µg	Administration:	intraperitoneal injection; three times of week for 21 days	Result:	Increased serum titers of anti-collagen Abs and few overt signs of disease.	Animal Model:	BALB/c mice <sup>[1]</sup>	Dosage:	100 µg	Administration:	intraperitoneal injection; three times of week for 14 days	Result:	Reduced mature B cell populations but had little effect on other cell lineages. Blocked the development of B cells at the transition from T1 to T2 and the development of MZ B cells in the spleen. Decreased the serum levels of IgM about 2.3-fold.
Animal Model:	Male DBA/1 mice with CIA models <sup>[1]</sup>																
Dosage:	100 µg																
Administration:	intraperitoneal injection; three times of week for 21 days																
Result:	Increased serum titers of anti-collagen Abs and few overt signs of disease.																
Animal Model:	BALB/c mice <sup>[1]</sup>																
Dosage:	100 µg																
Administration:	intraperitoneal injection; three times of week for 14 days																
Result:	Reduced mature B cell populations but had little effect on other cell lineages. Blocked the development of B cells at the transition from T1 to T2 and the development of MZ B cells in the spleen. Decreased the serum levels of IgM about 2.3-fold.																

### REFERENCES

[1]. Gross JA, et, al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BlyS. Immunity. 2001

---

Aug;15(2):289-302.

[2]. Gross JA, et, al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000 Apr 27;404(6781):995-9.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA